1887
Volume 2025, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

is an uncommon opportunistic yeast increasingly recognized as a cause of invasive fungal infections, particularly in immunocompromised patients and those with indwelling medical devices. Clinical experience remains limited, with most published cases involving neonates or adults with significant comorbidities.

We report a case of . fungemia in a 26-year-old man with end-stage renal disease on maintenance hemodialysis via a long-term tunneled catheter. The patient presented with fever following dialysis and was found to have leukocytosis and elevated inflammatory markers. Blood cultures from both peripheral and catheter sites grew yeast after 48 hours. Empiric antibacterial therapy was initiated, and the hemodialysis catheter was removed. Antifungal treatment with anidulafungin was started, leading to clinical improvement. Species identification was achieved using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), which revealed . . Antifungal susceptibility testing demonstrated low minimum inhibitory concentrations (MICs) for echinocandins and variable susceptibility to azoles. The patient completed a 14-day course of anidulafungin with full recovery.

This case underscores the importance of accurate identification of rare yeasts such as . , which may be misidentified as other less pathogenic species. MALDI-TOF MS and molecular diagnostics are critical tools for early detection. Due to its potential for azole resistance and biofilm formation, echinocandins appear to be an effective treatment option. Prompt catheter removal and appropriate antifungal therapy were pivotal to the patient’s successful outcome.

. should be considered in patients with fungemia and risk factors for invasive candidiasis, especially when initial identification is inconclusive. Awareness of this emerging pathogen and its management is essential to ensure timely intervention and improve clinical outcomes.

© 2025 Huda, Yasir, Mughal, Arif, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.90
2025-09-16
2025-12-16

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/3/qmj.2025.90.html?itemId=/content/journals/10.5339/qmj.2025.90&mimeType=html&fmt=ahah

References

  1. Wang CH, Su YS, Lee WS. Cyberlindnera fabianii fungemia complicating psoas muscle abscess successfully treated by surgical drainage and echinocandin therapy. J Microbiol Immunol Infect. 2023 06; 56:(3):644–6.https://doi.org/10.1016/j.jmii.2022.11.001
     [Google Scholar]
  2. Hamal P, Ostransky J, Dendis M, Horváth R, Ruzicka F, Buchta V, et al.. A case of endocarditis caused by the yeast Pichia fabianii with biofilm production and developed in vitro resistance to azoles in the course of antifungal treatment. Med Mycol. 2008 09; 46:(6):601–5.https://doi.org/10.1080/13693780802078180
     [Google Scholar]
  3. Lee JI, Yu S, Park JS, Joo EJ, Shin JH, Kwon M-J. Successful treatment of fungemia caused by Cyberlindnera fabianii with anidulafungin: a case report. Ann Clin Microbiol. 2015; 18:(3):94–97. https://doi.org/10.5145/ACM.2015.18.3.94
     [Google Scholar]
  4. Katagiri S, Gotoh M, Tone K, Akahane D, Ito Y, Ohyashiki K, et al.. Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation. Int J Hematol. 2016 05; 103:(5):592–5.https://doi.org/10.1007/s12185-016-1953-y
     [Google Scholar]
  5. Hof H, Amann V, Tauber C, Paulun A. Peritonitis in a neonate due to Cyberlindnera fabianii, an ascomycetic yeast. Infection. 2017 12; 45:(6):921–4.https://doi.org/10.1007/s15010-017-1062-8
     [Google Scholar]
  6. Al-Sweih N, Ahmad S, Khan S, Joseph L, Asadzadeh M, Khan Z. Cyberlindnera fabianii fungaemia outbreak in preterm neonates in Kuwait and literature review. Mycoses. 2019 01; 62:(1):51–61.https://doi.org/10.1111/myc.12846
     [Google Scholar]
  7. Kawasaki K, Sawai T, Inadomi Y, Morimitsu S, Ikeda T, Yoshioka S, et al.. Central venous access Port-Related blood stream infection caused by Cyberlindnera fabianii : a case report and literature review. J Infect Chemother. 2025 04; 31:(4):102662.https://doi.org/10.1016/j.jiac.2025.102662
     [Google Scholar]
  8. Arastehfar A, Fang W, Al-Hatmi AMS, Afsarian MH, Daneshnia F, Bakhtiari M, et al.. Unequivocal identification of an underestimated opportunistic yeast species, Cyberlindnera fabianii, and its close relatives using a dual-function PCR and literature review of published cases. Med Mycol. 2019 10 1; 57:(7):833–40.https://doi.org/10.1093/mmy/myy148. Erratum in: Med Mycol. 2019 Nov 1;57(8):e12. https://doi.org/10.1093/mmy/myz025
     [Google Scholar]
  9. Ira AVB, Krasteva D, Kouadjo F, Roger F, Bellet V, Koffi D, et al.. Four uncommon clinical fungi, Lodderomyces elongisporus, Kodamaea ohmeri, Cyberlindnera fabianii and Wickerhamomyces anomalus, isolated in superficial samples from Côte d’Ivoire. J Mycol Med. 2023 08; 33:(3):101410.https://doi.org/10.1016/j.mycmed.2023.101410
     [Google Scholar]
  10. Sasi S, Hadi HA, Chaponda M, El Ajez R, Ataelmanan M, Khasawneh S, et al.. Risk of serious infections in patients treated with biologic or targeted-synthetic disease modifying antirheumatic drugs in Qatar. Immun Inflamm Dis. 2025 04; 13:(4):e70195.https://doi.org/10.1002/iid3.70195
     [Google Scholar]
  11. Cornely OA, Sprute R, Bassetti M, Chen SC, Groll AH, Kurzai O, et al.. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM [published correction appears in Lancet Infect Dis. 2025 04; 25:(4):e203.https://doi.org/10.1016/S1473-3099(25)00154-9. [published correction appears in Lancet Infect Dis. 2025 May;25(5):e261. https://doi.org/10.1016/S14733099(25)00252-X.]. Lancet Infect Dis. 2025;25(5):e280-e293. https://doi.org/10.1016/S1473-3099(24)00749-7
     [Google Scholar]
  12. Park JH, Oh J, Sang H, Shrestha B, Lee H, Koo J, et al.. Identification and antifungal susceptibility profiles of Cyberlindnera fabianii in Korea. Mycobiology. 2019 09; 47:(4):449–56.https://doi.org/10.1080/12298093.2019.1651592
     [Google Scholar]
  13. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al.. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 02; 62:(4):e1–e50.https://doi.org/10.1093/cid/civ933
     [Google Scholar]
  14. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, et al.. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update [published correction appears in Am J Kidney Dis. 2021 04; 77:(4):551.https://doi.org/10.1053/j.ajkd.2021.02.002. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. https://doi.org/10.1053/j.ajkd.2019.12.001
     [Google Scholar]
  15. Miller DL, O’Grady NP; Society of Interventional Radiology. Guidelines for the prevention of intravascular catheter-related infections: recommendations relevant to interventional radiology for venous catheter placement and maintenance. J Vasc Interv Radiol. 2012 08; 23:(8):997–1007.https://doi.org/10.1016/j.jvir.2012.04.023
     [Google Scholar]
/content/journals/10.5339/qmj.2025.90
Loading
Central line-associated Cyberlindnera fabianii fungemia: A case report and review of diagnostic and therapeutic challenges
Qatar Medical Journal 2025, 90 (2025); https://doi.org/10.5339/qmj.2025.90
/content/journals/10.5339/qmj.2025.90
/content/journals/10.5339/qmj.2025.90
Loading

Data & Media loading...

  • Article Type: Case Report
Keyword(s): case report, central venous catheter, Cyberlindnera fabianii, echinocandin therapy, fungemia, MALDI-TOF and State of Qatar

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error